Kui Cui
Assistant Professor
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (20)
Year:
2026
Endocytic adaptor proteins are essential regulators of intracellular trafficking, coupling receptor internalization with downstream signaling. Recent discoveries have deepened our understanding of how endocytic adaptor proteins contribute to both physiological and pathological processes in the vascular system. This review summarizes the emerging roles of key adaptor proteins—such as epsins, disabled-2, and adaptor protein 2—across multiple vascular cell types, including endothelial cells, vascular smooth muscle cells, and macrophages. These adaptors have diverse but essential functions, ranging from regulating angiogenic signaling and maintaining endothelial barrier integrity to modulating inflammatory responses, vascular smooth muscle cells phenotypic switching, lipid uptake, and structural remodeling of blood vessels. We also highlight advances in therapeutic strategies, such as nanomedicine, viral expression vectors, DNA nanostructures, and small molecule inhibitors that target endocytic adaptors and their function. Understanding the diverse and cell-specific roles of endocytic adaptor proteins is important for gaining insights into vascular disease mechanisms and uncovering novel targets for therapeutic interventions.
Year:
2026
Background The protein tyrosine phosphatase CD45 is expressed in all nucleated cells of the hematopoietic system and in mitral valve endothelial cells (ECs) undergoing endothelial-to-mesenchymal transition (EndoMT). Our recent work indicated that activation of endogenous CD45 in human endothelial colony-forming cells (ECFCs) induced expression of multiple EndoMT marker genes. We hypothesized that CD45 may contribute to atherosclerosis; however, detailed molecular mechanisms underlying how CD45 may contribute to EndoMT and the impact of therapeutic manipulation of CD45 expression in atherosclerosis are unknown. Methods We generated a tamoxifen-inducible EC-specific CD45-deficient mouse strain (EC-iCD45KO) on an ApoE-deficient (WT/ApoE −/− ) background and fed them a Western diet (WD) to produce atherosclerosis. We enriched mouse aortic ECs with anti-CD31 beads to perform single-cell RNA sequencing. Cellular, biochemical and molecular approaches were used to investigate the effect of endothelial CD45-specific deletion on EndoMT and lesion development in an ApoE −/− mouse model of atherosclerosis. Results EC-iCD45KO mice showed reductions in lesion development, plaque macrophage infiltration, and expression of cell adhesion molecules when compared to WT/ApoE −/− controls. Single-cell RNA sequencing revealed that loss of endothelial CD45 decreases EndoMT marker expression and TGF-β signaling in atherosclerotic mice, which is associated with reduction of lesions. Mechanistically, CD45 loss increases Fibroblast Growth Factor Receptor 2 (FGFR2) expression in mouse aortic ECs and Krüppel-like Factor 2 (KLF2) expression in the aortic root. Endothelial CD45-deficiency also inhibits EndoMT and TGFβ signaling in atherosclerosis. Conclusions Our findings demonstrate that genetic depletion of endothelial CD45 protects against EndoMT-driven atherosclerosis by promoting FGFR2 and KLF2 expression while inhibiting Transforming Growth Factor beta (TGFβ) signaling and EndoMT. Consequently, targeting endothelial CD45 may represent a novel therapeutic strategy to reduce EndoMT in atherosclerosis.
Year:
2026
Cell-cell communication (CCC) is crucial for cellular function and tissue homeostasis. Existing methods for protein-oriented CCC detection often overlook metabolite-mediated CCC (mCCC), and adapting them to mCCC analysis is challenging due to fundamental differences in the underlying biological mechanisms. To fill this gap, we developed MEBOCOST, an algorithm built on scRNA-seq and metabolic flux balance analysis to detect mCCC among single cells. Comprehensive benchmarking analyses based on simulation, spatial, CRISPR screen, and clinical patient data demonstrated the robustness of MEBOCOST in detecting biologically significant mCCC events. We applied MEBOCOST to scRNA-seq datasets of human white adipose tissues and unraveled macrophages were the predominant source of mCCC reprogramming in obese patients. Moreover, analysis in mice brown adipose tissue successfully recapitulated known and further uncovered new mCCC events, including a glutamine-mediated endothelial-to-adipocyte communication, which was experimentally verified to regulate adipocyte differentiation. Therefore, MEBOCOST is a valuable tool for researchers investigating mCCC in diverse biological contexts and disease samples. MEBOCOST is freely available at https://github.com/kaifuchenlab/MEBOCOST.
Year:
2025
BACKGROUND: Atherosclerosis is a chronic inflammatory disease characterized by the accumulation of lipid-laden foam cells and plaques within the arterial wall. Dysfunctional vascular smooth muscle cells (VSMCs), fibroblasts, endothelial cells, and macrophages contribute to disease progression. Here, we report that macrophage-specific expression of epsins, highly conserved endocytic adaptor proteins involved in clathrin-mediated endocytosis, accelerates atherosclerosis in Western diet–fed mice. METHODS: WT/Apoe −/− (wild-type/Apoe-deficient) mice and littermates with a LysM-DKO/Apoe −/− (myeloid-specific deletion of epsin 1/2 on an Apoe −/− background) were generated and fed a Western diet for 16 weeks. Single-cell RNA sequencing was conducted to investigate the cellular and molecular mechanisms regulated by macrophage epsins during atherosclerosis. Findings from single-cell RNA sequencing were validated through metabolic profiling, qRT-PCR (quantitative reverse transcription polymerase chain reaction), immunostaining, and coculture experiments to assess associated phenotypic changes. RESULTS: LysM-DKO/Apoe −/− mice exhibited significantly reduced atherosclerotic foam cell formation compared with WT/Apoe −/− controls. Single-cell RNA sequencing analysis identified 19 major cell types, including 6 VSMC and 5 macrophage subpopulations. Modulated VSMC1 and VSMC2 subtypes were associated with inflammation, migration, and VSMC-to-macrophage transition. These populations, along with foamy-Trem2 and inflammatory macrophages, were markedly reduced in LysM-DKO/Apoe −/− mice. Transition of modulated VSMC2 subtype into macrophages was significantly inhibited, as confirmed by both computational analysis and experimental validation. In addition, macrophage epsin deletion reversed endothelial dysfunction, suppressed cholesterol- and glucose-mediated signaling, and reduced expression of proinflammatory ligands IL (interleukin)-1β and TNF-α (tumor necrosis factor α). CONCLUSIONS: Macrophage epsin deletion limits foam cell formation and preserves VSMC and endothelial cell phenotypes and functions. These findings reveal a potential therapeutic strategy targeting macrophage epsins to combat atherosclerosis.
Year:
2025
Introduction: Endothelial cell dysfunction causes recruitment of inflammatory cells to the intima, initiating atheromatous plaque build-up. Atherosclerosis underlies myocardial infarction and stroke which remain leading causes of death in the US. Identifying key regulators that limit endothelial dysfunction is critical. We uncovered a previously unrecognized role of an endocytic adaptor protein, Disabled homolog 2 (Dab2), which regulates endocytosis and lysosomal degradation of receptor tyrosine kinases such as VEGFR2. We found that endothelial Dab2 promoted VEGF signaling during angiogenesis in diabetic wound healing. However, the mechanism how Dab2 in the endothelial cells protected endothelium function in atherosclerosis is unknown. Hypothesis: Endothelial Dab2 protects endothelial function under atherogenic conditions by promoting pulsatile shear (PS)-induced PI3K-Akt-eNOS signaling via endosomal trafficking. PS increases transcription factor KLF4 expression which activates Dab2 expression. Restoring Dab2 in the endothelium offers a therapeutic strategy to limit plaque progression. Methods and Results: We found reduced endothelial Dab2 expression in human atherosclerosis and ApoE-/- mice. We generated endothelial-specific inducible Dab2 knockout mice (EC-Dab2iKO) and crossed to ApoE-null background (EC-Dab2iKO/ApoE -/- ). Western diet-fed EC-Dab2iKO/ApoE -/- mice exhibited heightened arterial inflammation, more severe plaque formation, increased macrophage infiltration and reduced plaque stability. Single-cell RNA-seq, qPCR and western blot revealed that endothelial Dab2 depletion significantly upregulated pro-inflammatory markers and shear stress-related atherosclerotic pathways, indicating Dab2 protect against endothelial dysfunction by increasing PS-dependent eNOS activation via endosomal PI3K-Akt activation. ATAC-seq and ChIP-qPCR showed that KLF4 binds to Dab2 promoter. Using an in vitro PS flow channel to mimic atheroprotective flow, we found both Dab2 and KLF4 were increased. Using an endothelial-targeted engineered nanoparticle, we delivered Dab2 mRNA to the atherogenic endothelium to restore Dab2 function. It increased Dab2 level in the atheroma which restrains plaque progression in ApoE-/- mice. Conclusions: Our study reveals Dab2 as a key protector of atherogenic endothelium, linking PS and endothelial homeostasis via KLF4 and PI3K-Akt-eNOS signaling. Targeted restoration of Dab2 may represent a promising therapeutic approach for atherosclerosis.
Year:
2025
Introduction: CD47, an anti-phagocytic protein, is upregulated in human and murine atherosclerotic plaques. While systemic CD47 blockade reduces atherosclerosis by enhancing efferocytosis, it causes transient anemia due to red blood cell clearance, limiting clinical use. The role of endothelial CD47 in atherogenesis is unclear. We explore how endothelial CD47 promotes atherosclerosis by inhibiting efferocytosis and cholesterol metabolism. Hypothesis: We hypothesize that endothelial CD47 promotes atherosclerosis, in part, by impairing PPARγ-mediated cholesterol efflux and efferocytosis, leading to defective autophagy and exacerbating vascular inflammation. Methods: We utilized scRNA-seq alongside molecular, cellular, and biochemical assays to investigate the role of endothelial CD47 in regulating efferocytosis, autophagy, and inflammation. We have generated endothelial-specific CD47 knockout (EC-CD47iKO) atherosclerotic models on ApoE-/- background and PCSK9-AAV8-injected mice fed a Western diet. To assess therapeutic potential, mice with established atherosclerosis were treated with lipid nanoparticle–encapsulated siRNAs targeting endothelial CD47 (CD47 siLNP). Results: Endothelial-specific deletion of CD47 significantly reduced atherosclerotic plaque burden and necrotic core formation in both ApoE-/- and PCSK9-AAV8 mouse models. CD47-deficient endothelial cells showed decreased expression of pro-inflammatory genes and increased expression of efferocytic receptors (LRP1, MERTK, SIRPα). Macrophages from EC-CD47iKO mice also exhibited elevated expression of efferocytosis-related genes. Co-culture experiments with apoptotic Jurkat cells revealed enhanced PPARγ-dependent ABCG1-mediated cholesterol efflux in CD47-deficient ECs. Transcriptomic analysis of aortic ECs indicated inhibition of inflammatory markers, also enrichment of autophagy and lipid metabolism pathways. CD47 deletion improved vascular function, evidenced by increased eNOS phosphorylation, reduced ROS production, and elevated autophagic flux (increased LC3-II, decreased p62). Finally, the treatment of endothelial targeting CD47 silencing siLNPs significantly attenuated atherosclerosis progression in mice with established disease Conclusion: Endothelial CD47 promotes atherogenesis by impairing PPARγ-mediated efferocytosis and cholesterol efflux, thereby enhancing vascular inflammation. Targeting endothelial CD47 represents a promising cell-specific therapeutic strategy for advanced atherosclerosis
Year:
2025
Background The low-density lipoprotein receptor (LDLR) in the liver plays a crucial role in clearing low-density lipoprotein cholesterol (LDL-C) from the bloodstream. This process takes place mainly in the liver. Under atherogenic conditions, Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9), secreted by the liver, binds to LDLR on hepatocytes, preventing its recycling and enhancing its lysosomal degradation. This process reduces LDL-C clearance, promoting hypercholesterolemia. Epsins, a family of ubiquitin-binding endocytic adaptors, are key regulators of atherogenesis in lesional cells, including endothelial cells and macrophages. Given epsins’ canonical role in regulating endocytosis of cell surface receptors, we aimed to determine whether and how liver epsins contribute to PCSK9-mediated LDLR endocytosis and degradation, thereby impairing LDL-C clearance and accelerating atherosclerosis. Methods Liver-specific epsin knockout (Liver-DKO) atherosclerotic models were generated in ApoE -/- and PCSK9-AAV8-induced atheroprone mice fed on a Western diet. We utilized single-cell RNA sequencing, along with molecular, cellular, and biochemical analyses, to investigate the physiological role of liver epsins in PCSK9-mediated LDLR degradation. Additionally, we explored the therapeutic potential of nanoparticle-encapsulated siRNAs targeting epsins 1 and 2 in ApoE -/- mice with established atherosclerosis. Results Western diet (WD)-induced atherosclerosis was significantly attenuated in ApoE -/- /Liver-DKO mice compared with ApoE -/- controls, as well as in PCSK9-AAV8-induced Liver-DKO mice compared with PCSK9-AAV8-induced wild-type (WT) mice accompanied by reductions in blood cholesterol and triglyceride levels. Mechanistically, single-cell RNA sequencing of hepatocytes and aortas isolated from atherosclerotic ApoE -/- and ApoE -/- /Liver-DKO mice revealed epsin-deficient Ldlr hi hepatocytes with diminished lipogenic potential. Notably, pathway analysis of hepatocytes showed increased LDL particle clearance and enhanced LDLR-cholesterol interactions under WD treatment in ApoE -/- /Liver-DKO mice compared with ApoE -/- controls, correlating with decreased plasma LDL-C levels. Furthermore, pathway analysis of the aortas showed attenuated inflammation and endothelial activation, coupled with reduced lipid uptake, and enhanced cholesterol efflux under WD treatment in ApoE -/- /Liver-DKO mice compared with ApoE -/- controls. Moreover, the absence of liver epsins led to an upregulation of LDLR protein expression in hepatocytes. We further demonstrated that epsins bind LDLR via the ubiquitin-interacting motif (UIM), enabling PCSK9-mediated LDLR degradation. Depleting epsins abolished this degradation, thereby preventing atheroma progression. Lastly, targeting liver epsins with nanoparticle-encapsulated epsins siRNAs effectively ameliorates dyslipidemia and inhibits atherosclerosis progression. These results are consistent with findings showing an increased epsin1 and epsin2 expression in atherosclerotic cardiovascular disease patients. Conclusions Liver epsins drive atherogenesis by promoting PCSK9-mediated LDLR degradation, thereby elevating circulating LDL-C levels and heightening lesional inflammation. As such, targeting epsins in the liver represents a promising therapeutic strategy to mitigate atherosclerosis by preserving LDLR and enhancing LDL-C clearance in the liver.
Year:
2025
Background: The anti-phagocytic molecule CD47 is upregulated in the atherosclerotic plaques of patients with cerebrovascular disease; however, the molecular mechanisms responsible for the development and progression of atherosclerotic lesions have not been fully established. In this study, we postulate how endothelial-specific CD47 promotes endothelial-to-mesenchymal transition (EndoMT) in potentiating atherosclerosis and assess the efficacy of developing novel therapeutic interventions for cardiovascular disease. Methods: Using single-cell RNA sequencing (scRNA-seq), combined with molecular, cellular, and biochemical analyses, we investigated the role of endothelial CD47 in stimulating EndoMT using knock-out in ApoE-/- atherosclerotic mouse models. Results: ScRNA-seq revealed that CD47 promotes EndoMT, and the loss of endothelial CD47 inhibits EndoMT marker expression as well as transforming growth factor-beta signaling in vitro and atherosclerotic mice, which is associated with smaller lesions in Apoe-/- mouse model. In endothelial cells, CD47 hinders efferocytosis of senescent ECs and represses macrophage’s efferocytotic capacity to propel arterial inflammation and atherogenesis. Mechanistically, the interaction between CD47 and efferocytic receptor MerTK exacerbates inflammation by inhibiting the process of efferocytosis in endothelial cells and macrophages under atherogenic conditions. In response to atherogenic stimuli, endothelial CD47 upregulates the endocytic adaptor protein epsin, causing fibroblast growth factor receptor-1 (FGFR1) signal attenuation that upregulates TGF-β signaling and promoting EndoMT and potentiating atherosclerosis. Conclusion: We conclude that endothelial CD47 potentiates EndoMT during atherogenesis by increasing TGF-β signaling through FGFR1 internalization and degradation and targeted manipulating CD47 expression with precision nanomedicine offering a novel approach for mitigating cardiovascular disease.
Year:
2025
Introduction: Cardiovascular diseases are often associated with impaired responses from the endothelium. Endothelial cell dysfunction causes recruitment of immune and inflammatory cells to the intima, which initiate atheromatous plaque build-up. Transitioning from a stable to vulnerable atheroma fuels myocardial infarction and stroke, posing enormous health challenges. A novel and indispensable role for an endocytic adaptor protein called Disabled homolog 2 (Dab2) showed potential atheroprotective role, yet the molecular mechanisms and signaling pathways that direct Dab2 to combat arterial inflammation are completely unknown. Hypothesis: Dab2 safeguards endothelium function by curbing inflammation, preventing dysfunction, and restraining atheroma progression. Aims: To determine the role of Dab2 in protecting against endothelial dysfunction and to determine the therapeutic gain of Dab2 targeted delivery to the dysfunctional endothelium. Methods: We created endothelial-specific inducible Dab2 knockout mice (EC-Dab2iKO) and bred with ApoE-null background (EC-Dab2iKO/ApoE -/- ). We used western diet to build atherosclerosis mice model. RNA-seq was used to determine pathway changes. We also employed an innovative nanotechnology to deliver Dab2 mRNA. Results: Dab2 was downregulated in endothelium of human and mice aortic plaque. Western diet-fed EC-Dab2iKO/ApoE -/- mice exhibited heightened arterial inflammation and more severe plaque formation, with increased macrophage infiltration and reduced plaque stability in plaque. RNA-seq showed Dab2 depletion significantly increased pro-inflammatory markers and shear stress-related and atherosclerotic pathways. Dab2 protected against endothelial dysfunction by increasing pulsatile shear-dependent eNOS activation via promoting endosomal PI3K-Akt activation. To ensure the clinical relevance of our work, we employed an innovative atheroma-targeting nanoparticles with Lyp-1 peptide, to deliver Dab2 mRNA to the atherogenic endothelium to restore Dab2 function. This nanoparticles increased Dab2 expression in endothelial cell in vitro and restrained plaque progression in ApoE -/- mice. Conclusion: Dab2 protects against endothelial dysfunction during atheroma progression and is a downstream target gene of atheroprotective flow. The innovative targeting reagents will facilitate paradigm-shifting endeavor to provide a foundation for the development of new treatments to benefit patients at-risk for heart attacks and strokes.
Year:
2025
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2023
Year:
2023
Year:
2023
Year:
2023
Year:
2022
Collaborators (5)
Yao Wei Lu
Assistant Professor
University of Southern California
Hong Chen
Professor of Surgery
Boston Children's Hospital/Harvard Medical School
Douglas Cowan
Staff Scientist
Boston Children's Hospital
Da-Zhi Wang
Professor and director
University of South Florida
Allon Wagner
University of California, Berkeley
Make your next move.
Prepare your application
Review drafts before you send them.